Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells

NCT ID: NCT01548274

Last Updated: 2012-03-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effects of Sarpogrelate in endothelial progenitor cells of patients with atherosclerosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Endothelial progenitor cells play an important role in vasculogenesis and vascular repair. Sarpogrelate, a inhibitor of HT2A, is used an an anti-platelet drug, however, a direct effect in vascular cells is supposed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atherosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sarpogrelate

Sarpogrelate 300mg/day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with atherosclerosis

Exclusion Criteria

* Patients with high risk of bleeding
* Patients with pregnancy
* Patients with allergic reaction of Salpogrelate
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aichi Gakuin University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Keiko Naruse

Associate professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aichi-Gakuin University

Nagoya, Aichi-ken, Japan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Japan

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Keiko Naruse, M.D., Ph.D.

Role: primary

+81-52-759-2111 ext. 5369

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AGU-65

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Carotid Plaque Screening Trial in Smokers
NCT00548665 COMPLETED PHASE4
GLPG0492 Pharmacodynamics
NCT01538420 COMPLETED PHASE1
Carnosine for Peripheral Arterial Disease Patients
NCT05371145 RECRUITING PHASE1/PHASE2
TART - Troglitazone Atherosclerosis Regression Trial
NCT00116545 COMPLETED PHASE2/PHASE3